Status:
COMPLETED
Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Tobacco Dependence
Smoking Cessation
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
The addition of tDCS as an adjunct to pharmacotherapy is a novel approach but one that is grounded in a growing evidence-base.The primary objective of this research is to provide preliminary evidence ...
Detailed Description
While varenicline on its own is the most effective medication for smoking cessation, long-term abstinence is still relatively poor. The primary objective of this study is to evaluate the effectiveness...
Eligibility Criteria
Inclusion
- Male or Female
- Aged 19-65
- Treatment seeking smoker
- Daily smoker of CPD\>8
- Able to attend daily appointments for tDCS for the first 2 weeks and booster sessions for the next 10 weeks.
- Wiling to undergo 3 fMRI sessions
Exclusion
- Current/recent DSM-IV Axis I diagnosis
- Current use of psychoactive drugs or medications
- History of seizures/epilepsy
- Current use of NRT, e-cigarettes or other medications for smoking cessation
- Metal embedded in skull or implanted electrical devices
- No head injury (concussion or loss of consciousness for more than an hour)
- Contraindications to fMRI
- Contraindications to varenicline
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT03841292
Start Date
October 1 2018
End Date
January 31 2022
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T1P7